Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Flagship Pioneering is a venture creation firm established in 2000 and headquartered in Cambridge, Massachusetts. The firm focuses on advancing healthcare by inventing, building, funding, and scaling innovative biotechnology companies. Flagship Pioneering is recognized for its unique approach to company creation, which leverages scientific research and technological advancements to address significant health challenges. The firm has founded over 120 companies and has achieved a strong track record of successful exits, including 25 IPOs since 2013.
As of 2024, Flagship Pioneering manages an aggregate capital pool of $10.9 billion and has $14 billion in assets under management (AUM). The firm operates primarily in North America but has expanded its reach into the UK and Asia-Pacific regions to support collaborations and scaling. Flagship's model emphasizes internal company origination, creating 6-8 new companies each year, and it has a diverse portfolio that includes notable companies like Moderna and Generate:Biomedicines.
Flagship Pioneering invests primarily in the biotechnology sector, targeting early-stage companies that are developing transformative therapies and technologies. The firm focuses on pre-seed, seed, seed+, Series A, and Series A+ stages, with a check size that varies based on the specific opportunity. Flagship emphasizes a hands-on approach, collaborating closely with scientists and entrepreneurs to nurture groundbreaking ideas that can lead to significant advancements in healthcare and sustainability.
The firm’s investment thesis revolves around originating first-in-category bioplatform companies from internally developed scientific hypotheses. Flagship seeks to identify and support companies that can generate multiple products and address unmet medical needs. The geographic focus is primarily on North America, with a strong emphasis on biotechnology, drug discovery, AI-enabled life sciences, and sustainability.
Flagship Pioneering has developed a diverse portfolio of over 120 companies, including:
Noubar Afeyan (Founder & CEO) — Co-founder and board chair of Moderna and Generate:Biomedicines, Noubar has founded or helped build over 100 life science and technology startups. He previously founded PerSeptive Biosystems and played a key role in creating Celera Genomics after its acquisition. He holds a Ph.D. in Biochemical Engineering from the Massachusetts Institute of Technology.
Paul Biondi (Managing Partner) — Paul leads Flagship's product and partnering capabilities, including Pioneering Medicines and product innovation. He has 17 years of experience at Bristol Myers Squibb, where he served as SVP of Strategy and Business Development. Paul is also on the boards of Tessera Therapeutics and Valo Health. He holds an MBA from Harvard Business School.
Lovisa Afzelius (General Partner) — A computational scientist, Lovisa has co-founded and led eight companies since joining Flagship in 2020, including Alltrna and Apriori Bio. She previously built and led Pfizer's systems immunology function and held roles at AstraZeneca and BioChromix Pharma. Lovisa holds a Ph.D. in Computational Biology from the University of Cambridge.
In April 2026, Flagship Pioneering launched Serif Biomedicines, focusing on developing Modified DNA medicines, with an initial commitment of $50 million. This launch highlights Flagship's ongoing commitment to advancing biotechnology solutions.
In July 2024, Flagship announced a successful capital raise of $3.6 billion for Fund VIII, which is intended to support the creation and development of an estimated 25 breakthrough companies across human health, sustainability, and AI. This fundraise significantly enhances Flagship's ability to invest in transformative therapies and technologies.
What are Flagship Pioneering's investment criteria?
Flagship Pioneering primarily invests in early-stage biotechnology companies that are developing transformative therapies and technologies. The firm looks for companies that can generate multiple products from a single scientific hypothesis.
How can founders apply or pitch to Flagship Pioneering?
Founders interested in pitching to Flagship should prepare a detailed presentation that outlines their scientific hypotheses, potential market impact, and how their work aligns with Flagship's focus on biotechnology and healthcare.
What makes Flagship Pioneering different from other venture capital firms?
Flagship Pioneering acts not only as an investor but also as an inventor and company builder. The firm emphasizes internal company origination and collaborates closely with scientists and entrepreneurs to develop innovative solutions.
What is the geographic scope of Flagship Pioneering's investments?
Flagship Pioneering primarily focuses on North America but has expanded its operations into the UK and Asia-Pacific regions to support collaborations and scaling.
What is the typical check size for investments?
While specific check sizes are not disclosed, recent examples indicate that initial commitments can be substantial, such as the $50 million commitment for Serif Biomedicines.
What kind of post-investment involvement does Flagship Pioneering have?
Flagship Pioneering provides comprehensive support to its portfolio companies, including scientific expertise, strategic partnerships, and access to capital, ensuring that they have the resources needed to succeed.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.